FDA Approval Insights: Talquetamab in Relapsed/Refractory Multiple Myeloma

0 Lượt xem· 09/07/23
OncLive® On Air
OncLive® On Air
0 Người đăng ký
0
Trong

Dr Minnema discusses the FDA approval of talquetamab in patients with relapsed/refractory multiple myeloma, key data from the MonumenTAL-1 trial, and the importance of designing clinical trials to address unmet patient needs.

Cho xem nhiều hơn

 0 Bình luận sort   Sắp xếp theo


Tiếp theo